.-The type IIb sodium-phosphate (NaPi-IIb) cotransporter mediates intestinal phosphate absorption. Previous work in our laboratory has shown that EGF inhibited NaPiIIb cotransporter expression through transcriptional regulation. To understand this regulation, progressively shorter human NaPi-IIb promoter constructs were used to define the EGF response region, and gel mobility shift assays (GMSAs) were used to characterize DNA-protein interactions. Promoter analysis determined that the EGF response region was located between Ϫ784 and Ϫ729 base pair (bp) of the promoter. GMSAs and overexpression studies revealed an interaction between this promoter region and c-myb transcription factor. Inhibition of EGF receptor activation restored promoter function. Further studies suggested that MAPK, PKC, and/or PKA pathways are involved in this regulation. In conclusion, these studies suggest that EGF decreases human NaP i-IIb gene expression by modifying the c-myb protein such that it inhibits transcriptional activation. We further conclude that this downregulation of promoter function is mediated by EGF-activated PKC/PKA and MAPK pathways. This is the first study that demonstrates involvement of c-myb in the regulation of intestinal nutrient absorption.
PHOSPHATE (P i ) plays a major role in growth, development, bone formation, and cellular metabolism. P i (re)absorption occurs in the small intestine and the kidney, mainly through sodium-dependent pathways. Type II sodiumdependent P i (NaP i -II) cotransporters are the major proteins involved in these processes. The type IIb sodiumdependent P i (NaP i -IIb) cotransporter is responsible for intestinal P i absorption, whereas the type IIa sodiumdependent P i (NaP i -IIa) cotransporter is critical for renal P i reabsorption. Many physiological factors regulate P i homeostasis via modulating P i absorption in the kidney and intestine. Specifically in the small intestine, low-P i diet, as well as 1,25(OH) 2 vitamin D 3 , stimulate P i absorption by elevating NaP i -IIb cotransporter activity (18, 44) , whereas glucocorticoids reduce P i absorption by decreasing NaP i cotransporter function (4, 10, 39) .
Epidermal growth factor (EGF), a growth hormone, also regulates renal and intestinal P i absorption. EGF has been shown to inhibit renal P i reabsorption by modulating NaP i -IIa mRNA expression (2, 3) . Our previous study also showed that EGF reduced NaP i -IIb mRNA synthesis in rat intestine and in human intestinal epithelial (Caco-2) cells by a transcriptional mechanism (46). Furthermore, a putative EGF response element(s) was shown to be in the region of Ϫ1,103 to Ϫ380 base pairs (bp) of the human NaP i -IIb (hNaP i -IIb) gene promoter.
EGF response elements have been identified as a serum-response element and AP1 binding sequences from the c-fos gene (15) and as Sp1 binding sequences from the rat preprothyrotropin-releasing hormone (33) and the human gastrin genes (16, 17, 25) . In the hNaP i -IIb gene promoter region (Ϫ1,103 to Ϫ380 bp), two sequences at position Ϫ792 to Ϫ786 bp (GG-GAAGG) and Ϫ479 to Ϫ474 bp (GGGCGC) were found to have high homology with the EGF response elements identified as Sp1 binding sequences from the rat preprothyrotropin-releasing hormone gene (33) . However, it is unclear whether these sequences are involved in EGF regulation of hNaP i -IIb cotransporter gene expression.
To determine whether these DNA sequences are involved in EGF regulation of hNaP i -IIb gene expression, we made a series of promoter constructs that contain different lengths of the 5Ј-flanking region of the hNaP iIIb gene upstream of a luciferase reporter gene and transfected these plasmids into Caco-2 cells to test the promoter response to EGF. DNA gel mobility shift assay (GMSA) was then used to detect interactions between DNA and nuclear proteins. From these results, we have shown for the first time that EGF regulation of hNaP i -IIb gene expression involves modulation of c-myb binding affinity as mediated by EGF activated PKC/PKA and MAPK pathways.
MATERIALS AND METHODS
Cell culture. Human intestinal epithelial (Caco-2) cells were purchased from American Type Culture Collection (ATCC) and cultured according to ATCC guidelines. Cells were cultured at 37°C in a 95% air-5% CO2 atmosphere and passaged every 72 h. In EGF treatment experiments, cells were incubated with 50 or 100 ng/ml EGF for 8 h before being harvested. Media and other reagents used for cell culture were purchased from Irvine Scientific (Irvine, CA). Cells between passages 40 and 46 were used in this study.
Assembly of reporter gene constructs. A series of progressively shorter hNaP i-IIb promoter constructs in the pGL-3/ basic luciferase reporter vector (Promega, Madison, MI) were made by restriction enzyme digestion or PCR (46). Briefly, pGL3/Ϫ1,103 bp construct was made by subcloning a SacIXmaI fragment of the hNaPi-IIb promoter into the pGL3/ Basic vector. For other deletion constructs, pGL3/Ϫ784 bp, pGL3/Ϫ729 bp, pGL3/Ϫ646 bp, pGL3/Ϫ624 bp, pGL3/Ϫ563 bp, and pGL3/Ϫ380 bp, different lengths of hNaP i-IIb promoter were PCR amplified, utilizing the same reverse primer and different forward primers containing sequences for SacI. These PCR products were then ligated into SacI-XmaI digested pGL3/Basic plasmid and sequenced. All deletion constructs end on the 3Ј end at ϩ15 bp of the hNaPi-IIb gene.
The mutation of the c-myb binding sequence was introduced by PCR-based site-directed mutagenesis (7) . In this strategy, the desired promoter region was PCR amplified with primers containing mutated base pairs. The wild-type sequence in the promoter was then replaced by the PCR fragment containing the mutated bases using restriction enzyme digestion. All constructs were confirmed by sequencing on both strands.
Transient transfection, EGF treatment, and luciferase assays. Caco-2 cells were seeded in 24-well plates and maintained in a defined medium. When cells were 70% confluent, lipofectamine (Invitrogen, Carlsbad, CA)-mediated transfection was performed as previously described (46). Cells were treated with EGF (50 or 100 ng/ml; Austral Biological, San Ramon, CA) or vehicle for 8 h before harvest. Promoter reporter gene assays were performed using a dual luciferase assay kit according to the manufacturer's instructions (Promega). For EGF-signaling pathway studies, various inhibitors or vehicles were added to the transfected cells 2 h before EGF was added. A mouse monoclonal antibody against the human EGF receptor (Ab-3) was purchased from Oncogene Research Products (Boston, MA). Tyrphostin AG-1478 (called AG-1478 throughout) and PD-098059 were purchased from Sigma (St. Louis, MO). H7 was purchased from Calbiochem (San Diego, CA).
Preparation of nuclear extracts for GMSA. Nuclear extracts were prepared by a previously described method (38) from Caco-2 cells treated with EGF (100 ng/ml) or vehicle for 8 h. Synthetic double-stranded oligonucleotides were designed to cover the promoter region Ϫ799 to Ϫ727 bp. DNA oligonucleotides were end-labeled with [␥-32 P]ATP, and 4 g of nuclear extract were incubated with 1 ng of labeled probe in GMSA binding buffer containing 10 mM HEPES (pH 7.5), 1 mM EDTA, 50 mM NaCl, 1 mM dithiothreitol, and 50 g/ml poly[d(I-C)]. After incubation at room temperature for 20-30 min, the mixture was electrophoresed on a 6% polyacrylamide gel in 0.25ϫ Tris-boric acid-EDTA buffer. Gels were dried and exposed to X-ray film. For competition experiments, a 100-fold molar excess of unlabeled probe was added to the reaction mixture before the labeled probe was added. For supershift assays, 4 g of a rabbit polyclonal antibody raised against a recombinant protein corresponding to amino acids 500-640 from the COOH terminus of human c-myb or nonspecific rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) were added to the reaction mixtures.
Cellular protein preparation. Cells were rinsed twice with PBS buffer and incubated in cell lysis buffer containing 0.45 ϫ PBS (pH 7.4), 0.5% Na-deoxycholate, 1% NP-40, 0.1% SDS, 2 mM PMSF, and protease inhibitor cocktail (Boehinger Mannheim, Indianapolis, IN) for 30 min at 4°C. Cells were scraped and passed through a 21-gauge needle several times. The cell lysates were then spun down at 10,000 g for 10 min at 4°C. The supernatant, containing cellular protein, was stored at Ϫ70°C.
Western blotting. Nuclear protein (20 g) or cellular protein (40 g) was subjected to SDS-PAGE (7.5%). The proteins were electroblotted to a membrane and reacted with an affinity-purified rabbit c-myb polyclonal antibody raised against an immunogenic peptide corresponding to amino acid residues 2-16 of the human c-myb protein (Active Motif, Carlsbad, CA). Immunodetection was performed using the BM chemiluminescence Western blotting kit (Roche Molecular Biochemicals, Mannheim, Germany). Nuclear proteins from the human chronic myelogenous leukemia (K562) cells (Active Motif) were used as a positive control for c-myb immunoblotting.
mRNA purification and PCR amplification. mRNA was purified from Caco-2 cells using the Micro FastTrack mRNA purification kit (Invitrogen). A reverse transcription reaction was performed in the presence of oligo(dT)15 primers and AMV reverse transcriptase. The primers used to amplify NaPi-IIb and ␤-actin gene products were the same as described previously (46). The primers used to detect the c-myb gene product were designed to cover the human c-myb cDNA (accession no. NM005375) region from 439 to 701 bp. Semiquantitative RT-PCR, as previously described (46), was used to determine the NaPi-IIb and c-myb gene expression levels in the absence or presence of EGF.
Overexpression of human c-Myb in Caco-2 cells. Human c-myb cDNA was PCR amplified from Caco-2 cells between bp 110 to 2,037 bp. PCR products were cloned into the pCR2.1 vector (Invitrogen) and confirmed by sequencing. The PCR insert was then moved into the mammalian expression vector pTarget (Promega) by restriction enzyme digestion. Recombinant plasmids were transfected into Caco2 cells by Fig. 1 . Identification of the promoter region responsible for EGF downregulation of human type IIb sodium-phosphate (hNaPi-IIb) cotransporter gene expression by deletion analysis. A series of progressively shorter hNaPi-IIb promoter constructs were transfected into Caco-2 cells, and EGF treatment was conducted before promoter assays were performed. Relative change is shown as the ratio of luciferase activity in EGF-treated cells over luciferase activity in vehicle-treated cells. Results are means Ϯ SE from 9 independent experiments done on different days. *P Ͻ 0.01 for pGL3/Ϫ784 and pGL3/Ϫ1,103 vs. others. Basic indicates the promoterless pGL3/Basic vector.
Lipofectamine (Invitrogen/GIBCO). Forty-eight hours after transfection, G418 was added (1 mg/ml) to the standard culture medium for 3 days, and the cells were lysed in 20 mM HEPES (pH 7.9), 0.4 M NaCl, 25% glycerol, 1 mM EDTA, 2.5 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride on ice for 20 min. Cell extracts were then frozen, thawed, and centrifuged for 10 min at 13,000 g at 4°C. Supernatants were collected and stored at Ϫ80°C until use (40) .
Statistical analysis. ANOVA post hoc tests (StatView 5.0.1; SAS Institute, Cary, NC) were used to compare values of experimental data. P values of Ͻ0.05 were considered significant.
RESULTS

Identification of the EGF responsive region in the hNaP i -IIb promoter.
A series of 5Ј deletion constructs was made between Ϫ1,103 and Ϫ380 bp of the hNaP iIIb promoter region. Caco-2 cells were transfected with these promoter constructs and treated with EGF (100 ng/ml) or vehicle for 8 h. Promoter reporter gene assays showed that deletion constructs pGL3/Ϫ563, pGL3/ Ϫ624, pGL3/Ϫ646, and pGL3/Ϫ729 did not respond to EGF treatment, whereas the constructs pGL3/Ϫ784 and pGL3/Ϫ1,103 were suppressed by EGF (Fig. 1) .
GMSA identification of DNA sequences involved in the EGF response of the hNaP i -IIb promoter. To identify the precise DNA sequences involved in the EGF response, four DNA oligos were designed to overlap the promoter region Ϫ799 to Ϫ727 bp. As shown in Fig. 2A , a low molecular weight DNA-protein interaction band was obtained from all the oligos used, whereas a higher molecular weight DNA-protein interaction band was observed with only the probe covering the promoter region Ϫ751 to Ϫ727 bp. Furthermore, the higher molecular weight-shifted band, but not the lower molecular weight-shifted band, was reduced by EGF administration. Therefore, the lower molecular weightshifted band was considered nonspecific, and we felt that it was most likely not involved in EGF regulation of hNaP i -IIb cotransporter gene expression.
Mutation at promoter region Ϫ739 to Ϫ734 bp abolished nuclear protein binding. To further define the DNA-protein interaction at Ϫ751 to Ϫ727 bp, mutant DNA oligos (Fig. 2B ) covering different parts of this region were used. Nuclear protein (4 g) from Caco-2 cells was incubated with labeled probe 751/727 in the presence or absence of a 100-fold excess of mutant or wild-type DNA oligos. As shown in Fig. 2B , wild-type DNA oligos completely competed the binding of nuclear proteins in shifted complex a. Mutant oligos (m2 and m2a) containing the wild-type sequence (739 bp Fig. 2 . Identification of the DNA sequences involved in EGF regulation of hNaPi-IIb expression by gel mobility shift assays (GMSAs). A: identification of the promoter region involved in EGF regulation. Nuclear protein (4 g) was purified from EGF or vehicle-treated Caco-2 cells and was incubated with 1 ng of labeled DNA oligos that cover the hNaPi-IIb promoter region (Ϫ799 bp to Ϫ727 bp) at 25°C for 20 min. A schematic of the 4 oligos is shown above. A specific shifted band (a) was detected with DNA oligo 751/727, which covers hNaPi-IIb promoter region Ϫ751 to Ϫ727 bp. EGF treatment reduced this specific binding. The lower band is likely not important for EGF regulation because it appears in all reactions and is not affected by EGF. The image presented here represents 1 of 4 independent experiments that showed similar results. B: identification of specific DNA sequences involved in the DNA-protein interaction. Nuclear protein (4 g) was purified from nontreated Caco-2 cells and was incubated with 1 ng of labeled DNA oligo 751/727 at 25°C for 30 min in the presence of 100-fold excess unlabeled competitors (oligo sequences shown above). The competitor oligos (m2, m2a, and m5) containing 5Ј-AACTGG-3Ј sequences (shown in boxes) competed for nuclear protein binding with the labeled probe. The competitor oligos (m1, m3, and m4) containing mutations within the 5Ј-AACTGG-3Ј sequence (mutations shown in bold) could not compete for nuclear protein binding. The image presented here is representative of 1 of 5 independent experiments that showed similar results. NE, nuclear extract; a indicates the specific DNA-protein complexes.
-AACTGG-734 bp) also competed binding of nuclear proteins in shifted complex a. Other mutant oligos (m1, m3, and m4), which have mutations of the -AACTGGsequence, had no effect on shifted complex a. The mutant oligo m5, which has upstream bps mutated, reduced the binding in complex a.
Functional confirmation of the DNA sequence involved in EGF regulation. To determine whether the DNA sequence (-AACTGG-) identified by GMSAs plays a functional role in EGF regulation of the hNaP i -IIb gene expression, the wild-type sequence in the promoter construct pGL3/Ϫ784 was replaced by mutant sequence 5Ј-TCTGTT-3Ј. The mutant promoter construct pGL3/Ϫ784m was then transfected into Caco-2 cells, and promoter activity was measured by promoter-reporter assays after EGF treatment. As shown in Fig. 3 , EGF treatment did not affect promoter activity in constructs pGL3/Ϫ380 or pGL3/Ϫ729, but it reduced promoter activity in promoter construct pGL3/Ϫ784-transfected cells (as also shown in Fig. 1 ). This reduction by EGF was abolished in mutant promoter construct pGL3/Ϫ784m-transfected cells. Promoter activity was similar in pGL3/Ϫ784m DNA-transfected cells as in other promoter construct-transfected cells in the absence of EGF (data not shown).
Identification of the protein interacting with the DNA sequence involved in EGF regulation by supershift assay. GMSA and functional studies suggested that the DNA sequence (bp 739 5Ј-AACTGG-3Ј bp 734) in the hNaP i -IIb promoter is the potential cis-acting element involved in EGF regulation. A search for transcription factor binding motifs within this region suggested a potential consensus binding site (-AACT/GG-) for the c-myb transcription factor. To determine whether this DNA sequence could be bound by c-myb protein, supershift GMSAs were performed. As shown in Fig. 4A , the nuclear protein bound to the probe (751/727) caused a specific band shift, and this band could be partially 3 . Effect of the sequence mutation on the hNaPi-IIb promoter response to EGF. The DNA region 5Ј-AACTGG-3Ј, identified in Fig.  2 , was replaced by the mutant sequence 5Ј-TCTGTT-3Ј in the pGL3/784 construct, and this construct was transfected into Caco-2 cells. Promoter assays were performed after EGF treatment. Relative change is shown as the ratio of luciferase activity in EGF-treated cells over luciferase activity in vehicle-treated cells. Results are means Ϯ SE from 7 independent experiments done on different days. *P Ͻ 0.03 for pGL3/Ϫ784 vs. others.
supershifted by an anti-c-myb antibody. As a control to demonstrate specificity of the c-myb antibody, we showed that the addition of rabbit IgG to the reaction did not produce a supershift. To further exemplify c-myb binding to the hNaP i -IIb promoter, human cmyb cDNA was overexpressed in Caco-2 cells, and the cytoplasmic extracts were used for GMSAs. As shown in Fig. 4B , the cell lysate from c-myb cDNA-transfected cells (pT-myb) generated an identical band shift to that seen with Caco-2 cell nuclear extracts. Conversely, cell lysate from vector DNA-transfected cells (pT) did not produce a band shift. These data, when considered together, indicate that the protein bound to this hNaP iIIb gene promoter region is c-myb.
Quantitation of endogenous c-myb gene expression in Caco-2 cells. Our studies suggested that c-myb protein is possibly involved in regulation of hNaP i -IIb gene expression by EGF. To further confirm that Caco-2 cells endogenously express the c-myb gene, mRNA was purified from EGF-or vehicle-treated Caco-2 cells, and semiquantitative RT-PCR was used to quantitate cmyb gene expression. As shown in Fig. 5 , c-myb mRNA could be detected in Caco-2 cells. Furthermore, EGF treatment reduced hNaP i -IIb mRNA expression but had no effect on c-myb or ␤-actin (used as a constitutive control) mRNA expression levels.
Quantitation of endogenous c-myb protein expression by Western blotting.
To determine endogenous c-myb protein distribution and expression levels, total cellular proteins and nuclear proteins were prepared from Caco-2 cells treated with EGF or vehicle. As shown in Fig. 6 , a protein at ϳ80 KDa was detected by the antibody against the NH 2 terminus of the human cmyb protein from both nuclear and cellular protein samples. EGF treatment did not alter c-myb protein expression levels or its cellular distribution in Caco-2 cells.
c-Myb involvement in hNaP i -IIb gene regulation is mediated through EGF receptor tyrosine kinase signaling transduction pathway.
It is known that EGF can exert its effects on gene expression through various signal transduction pathways. To further elucidate the pathway involved in the regulation of hNaP i -IIb gene expression, various EGF receptor-signaling pathway blockers were used. Caco-2 cells were transfected with promoter construct pGL3/Ϫ784 and pretreated with various inhibitors for 2 h before EGF was added. As shown in Fig. 7 , hNaP i -IIb gene promoter activity was reduced 32% by 50 and 100 ng/ml EGF in transfected Caco-2 cells. Administration of 50 nM monoclonal EGF receptor antibodies blocked the response of hNaP i -IIb promoter to EGF treatment (50 ng/ml; Fig. 7A ). AG-1478, a specific inhibitor of EGF receptor tyrosine kinase activity, also abolished the EGF effect on the hNaP i -IIb promoter at concentrations of 1 and 5 M (Fig. 7B) . Furthermore, administration of inhibitors PD-098059 (25 M) and H7 (10 M) inhibited 30 and 60% of the promoter response, respectively. The combination of PD-098059 and H7 completely blocked the response of hNaP i -IIb promoter to EGF (Fig. 7C) .
Tyrphostin AG-1478 inhibited the response of hNaP iIIb gene promoter to EGF by restoring the interaction between nuclear protein and DNA. Functional promoter analysis results showed that AG-1478 completely blocked the effect of EGF on hNaP i -IIb promoter activity. We therefore treated Caco-2 cells with 1 M AG-1478 and purified nuclear protein for GMSA to determine whether the DNA-protein interaction was restored. As shown in Fig. 8 , EGF treatment reduced the specific binding of nuclear protein to the probe 751/727. However, in the presence of 1 M AG-1478, binding levels were restored. AG-1478 itself had no effect on this DNA-protein interaction.
DISCUSSION
P i is an essential element of the body, and its homeostatic regulation is thus important. EGF, as a growth hormone, plays an important role in modulating intestinal P i absorption in certain pathophysiological conditions, such as hyperphosphatemia induced by intestinal ischemia/injury (14, 20, 41) . Previous work in our laboratory has shown that EGF reduced NaP i -IIb gene expression in the rat intestine and in human intestinal epithelial (Caco-2) cells. EGF affected NaP i -IIb gene expression by inhibiting transcriptional activation in Caco-2 cells. The DNA region involved in this regulation was hypothesized to be located between bp Ϫ1,103 and Ϫ380 of the hNaP i -IIb gene promoter (45) . In the current studies, we further narrowed the EGF response region to bp Ϫ784 to Ϫ729 of the hNaP i -IIb promoter. This DNA region has no homology with known EGF response elements identified from the c-fos (15), the rat preprothyrotropin-releasing hormone (33), the rat prolactin (13), or the human gastrin genes (16, 17, 25) . These findings suggest that a novel EGF response element may be present in the hNaP i -IIb promoter.
The EGF-responsive region was further refined to bp Ϫ751 to Ϫ727 by GMSA and functional analysis in Caco-2 cells. In GMSAs, the DNA-protein complex (called a) was decreased by EGF treatment. Competition studies with mutant oligos from the Ϫ751 to Ϫ727 region showed that the sequence at bp Ϫ739 to Ϫ734 (5Ј-AACTGG-3Ј) was critical for this DNA-protein interaction. When this wild-type DNA sequence in the hNaP i -IIb promoter was replaced by a mutant DNA sequence (5Ј-TCTGTT-3Ј), this DNA-protein interaction and the functional response of the hNaP i -IIb promoter to EGF were abolished. These results strongly suggest that this region is involved in EGF regulation of hNaP i -IIb gene expression.
Transcription factor binding motif searches suggested that the DNA sequence (5Ј-AACTGG-3Ј) identified in the hNaP i -IIb promoter could be recognized by the c-myb transcription factor. Additionally, supershift studies with an anti-c-myb antibody indicated that the c-myb transcription factor could bind to this EGF responsive sequence in the hNaP i -IIb promoter, suggesting a novel role for c-myb in EGF regulation. The fact that only a portion of the DNA-protein complex could be supershifted by c-myb antibody might be due to insufficient antibody affinity for c-myb protein or to low specific antibody concentration. Furthermore, we used cellular extracts from Caco-2 cells transfected with human c-myb cDNA in GMSAs and demonstrated that overexpressed human c-myb can bind to the hNaP i -IIb promoter oligo probe and produce an identical band shift to that seen with Caco-2 cell nuclear extracts. Overall, these data strongly suggest that the protein interacting at the EGF responsive site is c-myb.
c-Myb is a phosphorylated nuclear protein, which plays important roles in regulating cell growth, differentiation, and apoptosis (30) . c-Myb protein has three distinct regions, which are individually responsible for DNA binding, protein-protein interactions, and negative regulatory functions (26) . The COOH-terminal negative regulatory region of c-myb interacts with its DNA binding domain at the NH 2 -terminal region to influence trans interactions with transcriptional coactivators, cooperating proteins, or DNA (11, 29) . Studies have shown that c-myb function is regulated at the posttranslation level (28) . MAPK phosphorylates chicken c-myb protein at Ser-11/12, resulting in reduced DNA-binding activity (23, 24) . MAPK also phosphorylates homologous serines in mouse (Ser-528) and human (Ser-532) c-myb proteins, which also interferes with c-myb activity (5, 6, 43) . c-Myb is highly expressed in immature hemopoeitic cells and in the human intestine (35, 42) . It regulates the expression of many genes, Fig. 8 . Inhibition of EGF receptor tyrosine kinase activation restored the interaction between c-myb protein and the hNaPi-IIb gene promoter. Caco-2 cells were pretreated with 1 M AG-1478 for 2 h before being exposed to EGF. Nuclear proteins were then purified from these cells. GMSAs were performed in the presence of 4 g of nuclear protein and 1 ng of labeled oligo (751/727). a indicates the specific DNA-protein complexes. The image is representative of 4 independent experiments, which showed similar results.
such as myb-induced myeloid protein-1 (mim-1) (12), T cell surface markers CD4 (27, 37) , and CD34 (19) in immature hemopoeitic cells. However, little is known about the target genes of c-myb in intestinal epithelial cells.
Our results demonstrated that mutation of the cmyb-binding site abolished the EGF response of the hNaP i -IIb promoter. Further data suggested that cmyb binding to the promoter under basal conditions has no effect on transcriptional activation because mutation of the putative binding site did not alter basal promoter activity. But, upon EGF stimulation, c-myb is likely modified in some way that then leads to an inhibitory effect on transcriptional activation and decreased binding affinity on the hNaP i -IIb promoter. In fact, our data (as discussed in detail later) show that inhibition of MAPK or PKC activity could partially restore the activity of the hNaP i -IIb promoter, which suggests that MAPK-and/or PKC-mediated phosphorylation of c-myb induced by EGF signaling may be this proposed modification of c-myb. Furthermore, we found that inhibition of EGF receptor tyrosine kinase activity and EGF-EGF receptor interaction also abolished the effect of EGF on hNaP i -IIb promoter activity, presumably by blocking this modification of c-myb, which leads to its inhibitory properties on promoter function. Additionally, the findings that EGF did not alter c-myb mRNA abundance, c-myb protein expression levels, or distribution between cytosol and nucleus further suggested that the c-myb protein was modified by EGF treatment in Caco-2 cells. This possible posttranslational modification might involve changing protein-protein interaction(s) between c-myb and basal transcription factor(s) (28, 30) , which together may mediate the EGF response of the hNaP i -IIb gene.
EGF receptor signaling transduction pathways have been extensively studied. EGF receptor activation by EGF binding initiates multiple cellular signaling pathways. Ab-3, a mouse monoclonal antibody against the human EGF receptor, inhibits EGF binding to the EGF receptor and thus inhibits EGF-dependent tyrosine protein kinase activity. In preliminary experiments, we determined that 50 ng/ml EGF led to a maximal decrease in hNaP i -IIb gene expression and that 50 nM Ab-3 (the maximal concentration provided by the manufacturer) completely abolished this downregulation. Furthermore, we used an inhibitor of EGF receptor tyrosine kinase activity (tyrphostin AG-1478), which has been previously used at concentrations between 1 and 10 M (21, 34, 36) . These experiments showed that the response of the hNaP i -IIb promoter to EGF treatment could be completely blocked by treating transfected cells with 1 or 5 M tyrphostin AG-1478. Overall, these findings indicated that EGF downregulation of hNaP i -IIb gene expression involves EGF binding to its receptor, followed by EGF receptor tyrosine kinase activation.
Further experiments were performed to identify downstream pathways after EGF receptor activation by PD-098059, which is a highly specific inhibitor of MAPK activation and has been previously used at concentrations between 10 and 50 M (1, 21, 34 ). We chose 25 M for our experiments on the basis of these previous investigations. We also utilized H7, a potent inhibitor of both protein kinase C (PKC) and cAMPdependent protein kinase (PKA). In previous PKCsignaling pathway studies, the H7 concentration used was between 10 and 50 M (22, 31, 32) . We used the minimal dose of 10 M H7 for our experiments to avoid toxicity and nonspecific inhibition of other protein kinases. Our results with these inhibitors showed that administration of 10 M H7 reduced 60% of the promoter response to EGF and that 25 M PD-098059 reduced 30% of the promoter response to EGF. When used in combination, PD-098059 and H7 fully restored hNaP i -IIb promoter activity in the presence of EGF. These data suggest that both PKC and MAPK pathways are involved in EGF regulation of hNaP i -IIb gene expression, with less impact from the MAPK pathway. Because 10 M H7 could also inhibit PKA activity, PKA pathway involvement is possible.
PKC activation is known to be one of the downstream signals for EGF-induced receptor tyrosine kinase activation (9) . There are at least 12 PKC isoforms grouped into three subtypes identified to date, and each isoform has a unique, nonredundant role in signal transduction (8) . As an intestinal epithelial cell model, Caco-2 cells express at least five different PKC isoforms encompassing the three subtypes (8) . PKC activation by EGF has been shown to be related to protecting intestinal cells from oxidants/ethanol damage through PKC-␤1 (9) and PKC-(8) isoforms. Here, we observed that the downregulation of hNaP i -IIb gene promoter function by EGF could be partially restored by use of the PKC inhibitor H7, but this inhibitor is not isoform-specific, so it is currently unknown which PKC isoforms may be involved.
In summary, this study has identified the DNA sequence in the hNaP i -IIb gene promoter likely responsible for EGF downregulation of hNaP i -IIb gene expression. Supershift analysis and overexpression studies indicated that the transcription factor c-myb was responsible for binding to this sequence and that EGF treatment reduced binding affinity and concomitantly reduced promoter activity. Further work showed that EGF receptor tyrosine kinase-activated MAPK, PKC, and/or PKA pathways are involved in EGF modulation of hNaP i -IIb gene expression. These studies, for the first time, directly demonstrate c-myb regulation of a gene involved in intestinal nutrient absorption. Moreover, our data further exemplify a novel target gene (the NaP i -IIb cotransporter) of EGF receptor signaling in the mammalian intestine.
